Saxena, Mansi
van der Burg, Sjoerd H.
Melief, Cornelis J. M.
Bhardwaj, Nina http://orcid.org/0000-0003-1865-4187
Article History
Accepted: 25 February 2021
First Online: 27 April 2021
Competing interests
: C.J.M.M. is Chief Scientific Officer of ISA Pharmaceuticals in Leiden, Netherlands, a biotechology company aiming at commercial development of synthetic peptide-based therapeutic vaccines against cancers caused by high-risk human papillomaviruses and against non-viral cancers. He receives a salary as a full-time employee at ISA Pharmaceuticals and is a beneficiary of a management participation plan that goes into effect if the company reaches a predefined value inflection point in the future. C.J.M.M. is an inventor on several patents regarding the use of synthetic long peptides as therapeutic vaccines for treatment of premalignant and malignant lesions. S.H.v.d.B.is named as an inventor on a patent for the use of synthetic long peptides as a vaccine, serves as a paid member of the strategy board of ISA Pharmaceuticals and received honoraria as a consultant for PCI Biotech, IO Biotech and DC prime, which develop cancer vaccines. N.B. serves as an advisor/board member for Neon Therapeutics, Novartis, Avidea, Boehringer Ingelheim, Rome Therapeutics, Roswell Park Comprehensive Cancer Center, MD Anderson Cancer Center, BreakBio, Carisma Therapeutics, CureVac, Genotwin, BioNTech, Gilead and Tempest Therapeutics. N.B. is an extramural member of the Parker Institute of Cancer Immunotherapy. M.S. declares no competing interests.